

Date: 05/16/07

Pharmacy Announcement

Annual Preferred Drug List (PDL) Review – 2007:

The Pharmacy and Therapeutics Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy (DHCFP) is scheduled to perform an annual review of the PDL at their meeting scheduled for June 21, 2007. Drugs that will be considered for change and those drug classes without proposed changes are listed below. The Drug Class Reviews for those classes to be considered for change will be posted to the First Health Services website (<https://medicaid.nv.gov>) approximately 45 days prior to the meeting.

Submission of clinical information or comments pertaining to any of the drug classes listed below must be received no later than May 25, 2007. The clinical information submission process can be reviewed at <https://medicaid.nv.gov> (select "Drug Class Reviews" from the "Pharmacy" menu).

Drug classes with proposed changes have been determined based on the following criteria:

1. New drugs within the class since the last annual review.
2. Clinician's input and/or new compelling clinical evidence since the last annual review.
3. Classes the Committee has requested to be reviewed.
4. DHCFP recommendations based on changes in the National Medicaid Pooling Initiative (NMPI).

Drug Classes to be Considered for Change:

- Antidepressants: Novel
- Anti-Migraine Agents: Triptans
- Cardiovascular: Antihyperlipidemics: Statins and Statin Combinations
- Cardiovascular: Beta Blockers
- Central Nervous System: ADHD/Stimulants/Non-Stimulants
- Ophthalmic Antihistamines
- Respiratory: Beta-Adrenergic Agents, Long-Acting Inhaled
- Respiratory: Glucocorticoids, Inhalers

Drug Classes without Proposed Changes:

- Analgesics: Long-Acting Narcotics
- Antibiotics: Cephalosporins Second Generation
- Antibiotics: Cephalosporins Third Generation
- Antibiotics: Macrolides
- Antibiotics: Quinolones Second Generation
- Antibiotics: Quinolones Third Generation
- Antidepressants: SSRIs
- Antimetics: Oral, 5-HT3s
- Antifungals: Onychomycosis Agents
- Antihistamines: Second Generation

- Bone Ossification Agents: Bisphosphonates
- Cardiovascular: ACE Inhibitors & Diuretic Combinations
- Cardiovascular: Angiotensin II Receptor Blockers & Diuretic Combinations
- Cardiovascular: Antihyperlipidemics: Cholesterol Absorption Inhibitors
- Cardiovascular: Antihyperlipidemics: Niacin Derivatives
- Cardiovascular: Antihyperlipidemics: Triglyceride Lowering Agents
- Cardiovascular: Calcium Channel Blockers & ACEI Combinations
- Central Nervous System: Hypnotics
- Electrolyte Depleters
- Gastrointestinal Agents: H2RAs
- Gastrointestinal Agents: PPIs
- Hepatitis C Agents
- Herpetic Antiviral Agents
- Immunomodulators: Injectable
- Immunomodulators: Topical
- Leukotriene Modifiers
- Multiple Sclerosis Agents
- Nasal Calcitonins
- Ophthalmic Glaucoma Agents
- Ophthalmic Quinolones
- Otic Fluoroquinolones
- Respiratory: Anticholinergic Agents, Inhaled
- Respiratory: Beta-Adrenergic Agents, Short-Acting Inhaled
- Respiratory: Glucocorticoids, Nasal
- Urinary Antispasmodics